Altay Biopharma
About us
The Science
Pipeline
Team
Contact
Careers
About us





Altay Therapeutics discovers novel small molecule drugs that target disease-causing transcription factors






Novel Mechanism:
Our small molecules have potent inhibitor activity against disease-causing transcription factors by disrupting their association with DNA.

Robust Platform and screening approach:
Our novel approach enables the identification of new transcription factors as targets for a wide range of diseases. Using our know-how and robust drug screening approach, we are able to develop potent small molecule drugs targeting disease-causing transcription factors. 

Preclinical findings:
Our small molecules have shown exceptional results in several animal models for fibrotic diseases and several cancers. 
The Science

Altay develops novel small molecules that inhibit transcription factors that are validated drivers of disease. Our platform, enables us to identify new targets in a variety of therapeutic areas and generate inhibitors using our robust screening approach. Our mechanism of inhibition enables us to drug the "undruggable", giving us a leading advantage over our competitors.

Pipeline

Clinic by Q3 2022. We are focused on finding treatments for chronic inflammatory liver diseases such as NASH and liver cancer. We expect to nominate a lead drug for liver diseases by Q1 of 2021. 


Our pre-clinical studies for prostate cancer and Ewings Sarcoma show great efficacy. We expect to nominate a lead for our prostate cancer program by Q2 of 2021. 

Team

Founders


Ali Rayet Ozes. PhD.

Founder and CEO

  * Lead scientist. Mechanism of small molecules for oncology program - Nalo Therapeutics

  * Post-doctoral Researcher - Janssen Biopharma

  * University of California, Davis (B.S.)

  * Indiana University, Bloomington (PhD.) Biochemistry and Molecular Biology.


Osman Nidai Ozes. PhD.

Founder and CSO

  * Professor of Genetics. Mechanism of inflammatory response in cancer - Akdeniz University

  * Director of Research. Lead of Esbriet IPF program- Intermune Inc.

  * Haccettepe University, Ankara (B.S and M.S.)

  * Indiana University, Bloomiongton (PhD) Immunology




Scientific Advisors


Lee Latimer. PhD.

Medicinal Chemistry-Consultant

* Board of Directors, director-at-large - American Chemical Society (2016-2018)

* Senior Director, Process and Analytical Chemistry - Elan Inc. (1995-2011)

* University of Wisconsin (PhD.)



Kamran Atabai. MD.

Fibrosis Expert

* Associate Professor of Medicine - University of California San Francisco

* Fellowship - Pulmonary and Critical care - Harvard

* Residency - School of Medicine - University of California San Francisco

Paul Wolters. MD.

Fibrosis Expert

* Professor - University of California San Francisco

* Director - UCSF Interstitial Lung Disease Program

* Residency - University of Colorado

Aykut Uren. MD.

Ewing's Sarcoma Expert

* Professor - Georgetown University

* Assistant Director, Genomics and Epigenomics Shared Resource Advisory Committee

* Residency - Hacettepe University, Ankara



Contact

Altay is located at the Bayer Colaborator in San Francisco Mission Bay.

For more information please contact us:

info@altaytherapeutics.com

Address:

455 Mission Bay

Boulevard South

San Francisco, CA 94158

Careers

Please check back soon for upcoming opportunities to work with us!